Table 1.
Ramiro 2015 [2] | Ramiro 2014 [13] | Kang 2014 [6] | Braun 2013 [3] | Poddubnyy 2013 [10] | Chung 2012 [11]* | Tubergen 2012 [12] | ||
---|---|---|---|---|---|---|---|---|
Methods | Cohort | OASIS | OASIS | 67 women | GO-RAISE | GESPIC | DESIR | OASIS |
Outcome | Change in mSASSS | Change in mSASSS | New syndesmophytes | Change in mSASSS | mSASSS and new syndesmophytes | mSASSS | New syndesmophytes | |
Statistics | Multivariate | Univariate | Univariate | Univariate | Multivariate | Multivariate | Multivariate | |
Results | Existing syndesmophytes | yes | yes | yes | yes | - | - | yes |
CRP | - | yes | yes | yes | - | yes | no | |
Male gender | yes | - | - | - | - | yes | - | |
Smoking | - | - | - | - | yes | yes | - | |
Older age | - | - | yes | - | - | - | no | |
HLA-B27 | yes | no | - | - | - | no | no | |
Disease duration | no | - | yes | - | - | - | no | |
Symptom duration | no | - | - | - | - | - | no | |
Family history | - | - | - | - | - | yes | - | |
Sacroiliitis severity | - | - | yes | - | - | - | - | |
Age at onset of IBP | - | - | - | - | - | yes | - | |
BASDAI | - | yes | - | - | - | - | no | |
ASDAS | - | yes | - | - | - | - | no | |
Hip involvement | - | - | - | - | - | - | no | |
Extra-articular manifestation | - | no | - | - | - | - | - | |
ESR | - | no | - | - | - | - | no |
Indicates a cross-sectional study. Other studies are longitudinal.
(-) not studied or reported.
OASIS: Outcome in Ankylosing Spondylitis International Study; GO-RAISE: phase III clinical trial of Golimumab; GESPIC: German Spondyloarthritis Inception Cohort; DESIR: Devenir des Spondylarthropathies Indifférenciées Récentes; ; CRP: C-reactive protein; IBP: inflammatory back pain; BASDAI: Bath ankylosing spondylitis disease activity index; ASDAS: AS disease activity score; Extra-articular manifestations include psoriasis, inflammatory bowel disease and uveitis; ESR: erythrocyte sedimentation rate.